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Background and objectives: Ultrasonographic detection of subclinical 
atheromatosis is a noninvasive method predicting cardiovascular events. Risk 
factors predicting atheromatosis progression in chronic kidney disease (CKD) 
are unknown. Predictors of atheromatosis progression were evaluated in CKD 
patients. 
Design, setting, participants, & measurements: Multicenter, prospective 
observational study in 1553 CKD patients (2009-2011). Carotid and femoral 
ultrasounds were performed at baseline and after 24 months. A subgroup of 
476 CKD patients was also randomized to undergo ultrasound examination at 
12 months. Progression of atheromatosis was defined as an increase in the 
number of plaque territories, analyzed by multivariate logistic regression.  
 Results: Prevalence of atheromatosis was 68.7% and progressed in 59.8% of 
patients after 24 months. CKD progression was associated with atheromatosis 
progression, suggesting a close association between pathologies. Variables 
significantly predicting atheromatosis progression, independently from CKD 
stages, were diabetes and two interactions of age with ferritin and plaque at 
baseline. Given that multiple interactions were found between CKD stage and 
age, phosphate, smoking, dyslipidemia, body mass index (BMI), systolic blood 
pressure (SBP), carotid intima-media thickness (cIMT), plaque at baseline, uric 
acid, cholesterol, 25-hydroxi-vitamin D and antiplatelet and phosphate binders 
use, the analysis was stratified by CKD stages. In stage 3, two interactions (age 
with phosphate and plaque at baseline) were found and smoking, diabetes, 
SBP, low levels of 25OH vitamin D, and no treatment with phosphate binders 
were positively associated with atheromatosis progression. In stage 4-5, three 
interactions (age with ferritin and plaque, and plaque with smoking) were found, 
and SBP was positively associated with atheromatosis progression. In dialysis, 
an interaction between BMI and 25OH vitamin D was found and age, 
dyslipidemia, cIMT, low cholesterol, ferritin and uric acid were positively 
associated with atheromatosis progression. 
Conclusions: Atheromatosis progression affects more than half of CKD 
patients, and predictive factors differ depending on CKD stage. 
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INTRODUCTION 
 
Cardiovascular disease is the main cause of death in chronic kidney disease 
(CKD) patients, in which cardiovascular death is a more likely outcome than 
progression to end-stage renal disease (ESRD).1  Classical risk prediction 
equations underestimate cardiovascular disease risk in adults with CKD,2;3 in 
which most events occur in patients with low-moderate risk.4;5   Therefore, new 
tools for risk prediction in renal patients are needed. Arterial ultrasonography 
assessment of subclinical atheromatosis is a non-invasive imaging technique 
that could predict incidence of cardiovascular events better than traditional 
models.6-9 It has been shown that increases in plaque burden have a strong 
predictive value assessing cardiovascular events in dialysis patients10 and in the 
general population.7 However, data on patients in early stages of CKD are 
scarce.11  
Although numerous studies show an association between decreased kidney 
function and cardiovascular disease and mortality, mechanisms underlying this 
association are incompletely understood. This could be related to differences in 
cardiovascular events types and the associated factors amidst the progression 
of CKD. Thus, in early stages, there is a high mortality rate due to 
atherothrombotic ischemic events,12-14 but in dialysis mortality is mainly caused 
by heart failure and sudden cardiac death.15 Determining risk factors predicting 
atherosclerosis progression in every CKD stage could help to establish effective 
preventive measures to decrease cardiovascular disease in CKD patients. 
Recently, baseline data from the NEFRONA16 study have shown that patients in 
early CKD stages already have a higher prevalence of atheromatous plaques 
than those without CKD17;18 and as previously shown, this prevalence is even 
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higher in advanced stages of CKD.19-21 However, it is uncertain what the 
velocity of atheromatosis progression in CKD is22;23 and little is known about the 
predictors of plaque progression in CKD patients. Only two studies have 
addressed this question, one with dialysis patients,10 and another with a limited 
number of CKD stage 3-4 patients with a short interval ultrasound control.22  
We present here the first longitudinal results from the NEFRONA study, 
regarding the risk factors predicting progression of atheromatosis in a large 
CKD patient population. Furthermore we assessed whether atheromatosis 
progression is associated with CKD progression. 
 
METHODS 
Design & study population 
The protocol of the study was approved by the ethics committee of each 
hospital and all patients were included after signing informed consent. This 
research followed the principles of the Declaration of Helsinki. The design and 
objectives of the NEFRONA study have been published in detail.24;25 Briefly, 
2445 CKD patients (937 in CKD stage 3, 820 in stage 4-5 and 688 in dialysis) 
who were 18-75 years of age were enrolled from 81 Spanish hospitals between 
October 2009 and June 2011, with a scheduled follow-up visit after 24 months. 
Additionally, 476 CKD patients were randomly selected to undergo ultrasound 
examination also at 12 months. Patients from the NEFRONA study who had 
stenotic carotid plaque, ankle-brachial index (ABI) <0.7 at baseline, a 
cardiovascular event, received a renal allograft or died after the first ultrasound 
exploration were excluded from the follow-up visit.  
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Clinical data and Laboratory examinations 
Current health status, medical history, former cardiovascular risk factors and 
drug use information was obtained at baseline. A physical examination was 
performed, consisting of anthropometric measures, standard vital tests and ABI 
measurements as previously described.16 A pathological ABI was described as 
≤ 0.9 or ≥ 1.4. Biochemical data were obtained from a routine fasting blood test 
within three months from the vascular study.  Glomerular filtration rate (GFR) 
was estimated using the Modification of Diet in Renal Disease Study formula 
(MDRD-4). Parathyroid hormone (PTH) levels in dialysis patients were 
corrected using a well-established method to avoid inter-method variability 
between different centers.26 
Ultrasound Imaging 
B-mode ultrasound of the carotid and femoral arteries was performed using the 
Vivid BT09 apparatus (General Electric) equipped with a 6-13 MHz broadband 
linear array probe as previously described.27 An atheromatous plaque presence 
analysis was performed in 10 territories (both internal, bulb and common 
carotids, and both common and superficial femoral arteries) by a single reader 
in blinded fashion, using semi-automatic software (EchoPAC Dimension, 
General Electric Healthcare). To assess intraobserver reliability, a sample of 20 
individuals was measured 3– 5 times on different days. A kappa coefficient of 1 
was obtained for plaque assessment, indicating excellent intraobserver 
reliability. The reader was unaware of patients’ clinical histories.  
cIMT was only measured in common carotid regions without plaque and 
calculated as the average between left and right sides. The presence of 
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atheromatous plaques was defined as a cIMT > 1.5 mm protruding into the 
lumen, according to the ASE Consensus Statement28 and the Mannheim cIMT 
Consensus.29  
Evaluation of Progression  
Atheromatosis progression was defined as an increase in the number of 
territories showing a plaque with respect to the baseline visit, as previously 
used in the MESA study.30 Individuals doubling basal serum creatinine or 
starting renal replacement therapy were considered CKD progressive. Thus, 
patients in dialysis at baseline were excluded from this last variable.   
Statistical analysis 
Data are expressed as mean and standard deviation (SD) for quantitative 
variables and as relative frequencies for qualitative variables. In some 
quantitative variables in which nonlinear effects were detected, tertiles were 
used. 
The relationship between potential risk factors with plaque progression at 24 
months was analyzed by univariate and multivariate logistic regression. Chi-
square or Mc Nemar tests were used to compare qualitative variables between 
progression and non-progression; the Mann-Whitney test was used for 
quantitative variables. Significant variables in univariate analyses and potential 
confounders were used to develop appropriate multivariate logistic regression 
models: age, sex, diabetes, smoking status, BMI, SBP, triglycerides, ferritin, 
cholesterol, dyslipidemia, uric acid, CKD stage, 25-OH-vitamin D, cIMT, plaque 
at baseline, statins treatment, antiplatelet drugs. A forward step procedure was 
used to build the multivariate model, including the variable showing maximum 
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contribution identifying those patients with 24-month atheromatosis progression, 
according to the likelihood ratio test (LRT). Those variables without a 
statistically significant contribution, but modifying in more than 10% the value of 
the coefficients (β) of any of the significant variables when removed from the 
model, were considered confounders and included in the final model. The 
model with the contributing or confounding variables was assessed for 
interactions of first and second order in a backward procedure to optimize AIC 
criterion. The contribution of the interactions identified by the former procedure 
was assessed by the LRT test in order to discard those interactions without a 
statistically significant contribution to the model. In case an explanatory variable 
showed multiple interactions with other covariates in the model, the analysis 
was stratified by that variable to facilitate interpretation. A statistical significance 
level of 0.05 was used.  
All analyses were made using a standard statistical package (SPSS 21.0) and 
R program. 
RESULTS 
Baseline Characteristics 
From the original NEFRONA study cohort (2445 CKD patients), 888 were 
excluded from the 24-month analysis. Namely, deaths (46), cardiovascular 
events (80), renal allografts during the 2 years (359) and second visit non-
attendees (403). Finally, 1553 (709 CKD stage 3, 578 CKD 4&5 and 266 on 
dialysis) patients were included in the plaque progression analysis at 24 months 
because 4 presented plaque in all 10 territories at baseline. Furthermore, there 
were 476 patients who were also assessed after 12 months.  
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The cohort consisted of 61.6% men and mean age was 58.8 years. Of the 
patients, 29% were diabetic and 56% smokers.  Baseline characteristics in 
participants according to CKD stages are detailed in Table 1. The percentage of 
men, smokers and the average age were higher among CKD stage 3 patients. 
Dialysis patients showed lower body mass index (BMI), systolic blood pressure 
(SBP), total cholesterol, LDL-cholesterol, corrected serum calcium and 1-25-
dihydroxy vitamin D, whereas serum PTH and high-sensitive C-reactive protein 
(hsCRP) were higher. Atheromatous plaque prevalence was 68.7 % without 
significant differences between CKD stages. At baseline, 53% of patients had 
plaques in multiple territories and 16% had a single plaque; 37.2% had plaque 
in carotids and femorals, whereas 18.4% had plaque only in carotids and 13.1% 
exclusively in femorals. Prevalence of pathological ABI was 23.3%. The 
percentage of patients with pathological ABI was higher among patients in 
dialysis because of a high prevalence of ABI >1.4. 
 
Analysis of progression at 24 months 
The percentage of patients with plaque increased, from 68.6% to 81.4% at 24 
months.  Atheromatosis progression occurred in 59.8% of patients.  Mean 
number of territories with plaque increased from 3.16 (SD=1.97) to 4.48 
(SD=2.34). 
Baseline potential factors predicting atheromatosis progression in univariate 
analysis are detailed in Table 2. In a multivariate regression model, assessing 
all significant predictors in the univariate analysis (supplemental Table S1), 
only diabetes and two interactions of first order (age with ferritin and the 
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presence of plaque at baseline) were independent predictors of atheromatosis 
progression with a similar effect across all CKD stages. Thus, the association of 
ferritin and plaque with the progression of atherosclerosis decreased with age. 
Significant interactions were found between CKD stage and age, phosphate, 
smoking, dyslipidemia, BMI, SBP, CCA-IMT, plaque at baseline, uric acid, 
cholesterol, 25-hydroxi-vitamin D and antiplatelet and phosphate binders use, 
three of them of second order. Therefore, to better understand risk factors for 
progression of atheromatosis, a multivariate model stratified by CKD Stages 
was built. This decision was justified by the existence of multiple interactions of 
CKD stage with other clinical variables, and also because many of those 
parameters show a very wide range when individuals from different CKD stages 
are pooled together. For instance, PTH or phosphate levels stay relatively 
stable in early stages, increasing very steeply in dialysis.  
 
Atheromatosis progression at 24 months stratified by CKD stage 
Risk factors of atheromatosis progression were analyzed in each CKD stage 
(Table 3). In stage 3, age, SBP, smoking, phosphate, the lack of phosphate 
binders use, diabetes, plaque presence and low 25OH vitamin D significantly 
predicted progression of atheromatosis. Two interactions of age with phosphate 
and plaque at baseline were also found. In CKD stage 4-5, age, SBP, smoking, 
plaque presence and ferritin significantly predicted the formation of new plaque, 
with significant interactions of age with plaque and ferritin, and of smoking with 
plaque. In dialysis, factors associated with new plaque formation were age, 
basal cIMT, dyslipidemia, ferritin and uric acid, whereas BMI, total cholesterol 
10 
 
and 25-OH-vitamin D were inversely associated. A significant interaction was 
found between vitamin D and BMI.  
 
Presence of plaque at baseline, CKD progression and atheromatosis 
progression 
In contrast to patients with plaque at baseline, atheromatosis progression in 
patients free from disease at baseline was very low (Figure 1). Furthermore, 
bivariate analysis shows that the percentage of patients with atheromatosis 
progression was higher in the group with CKD progression (Table 2). Figure 2 
shows that progression of atheromatosis was significantly more frequent in 
patients with CKD progression. Figure 3 shows the percentage of patients with 
atheromatosis progression according to CKD progression and the presence of 
plaques at baseline. Almost 80% of patients in which CKD progressed and had 
plaque at baseline experienced aggravation of atheromatosis. At the other end, 
around 60% of patients in which CKD did not progress and were free of plaques 
at baseline, did not suffer an increase in atheromatous burden. Spearman 
correlation between progressors in both CKD and atheromatosis was positive 
and statistically significant (s=0.1, p=0.004). 
 
Atheromatosis progression at 12 months  
In one patient subgroup, progression of atheromatosis was also evaluated after 
12 months from the first visit and plaque progression was observed in 47% of 
the patients. Of those, 54% of them progressed even more at 24 months. Of the 
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non-progressors at 12 months, 38% progressed at 24 months. (Supplemental 
Figure S1).  
 
DISCUSSION 
In this work we analyze atheromatosis progression and the factors predicting it 
in a subpopulation of the NEFRONA study who did not suffer a cardiovascular 
event during the 24 months of follow-up. Our main findings are: 1) In CKD there 
is a high prevalence of patients with atheromatous plaque in carotid and/or 
femoral territories, but about 30% are free from atheromatosis.  Moreover, in 
about 40% of patients atheromatosis progression is absent after 2 years. 2) The 
only variables with a homogeneous association with the progression of plaque 
across CKD stages were the presence of diabetes and two interactions of age 
with ferritin and the presence of plaque at baseline. 3) Apart from those 
variables, risk factors predicting atheromatosis progression are different 
depending on the CKD stage. 4) The progression of atheromatosis is 
associated with the progression of CKD. 
The data also show that, although this is a population with high cardiovascular 
risk, a significant proportion of patients are free from 
atheromatosis. Interestingly, in these particular patients without plaque at 
baseline, atheromatosis progression is slow or nonexistent, suggesting a 
phenotype of individuals ‘protected’ from the disease. Identifying the phenotypic 
characteristics in these patients is of great interest to the study of the 
pathogenesis of atheromatosis.  
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The progression of atheromatosis was assessed by quantifying the number of 
carotid and femoral territories with plaque, as previously reported in other 
studies.30 Quantifying did not require special software (for a more sophisticated 
analysis such as plaque area or volume) and also predicts cardiovascular 
events more accurately than IMT.9 Benedetto et al showed that progression of 
atheromatosis is a better predictor of cardiovascular events than the baseline 
number of plaques in a cohort of ESRD patients,10 indicating that monitoring the 
evolution of plaque burden adds independent prognostic information. One 
novelty included in our study is the analysis of femoral arteries, which are not 
routinely explored. Our results indicate that if only carotid territories had been 
explored, the presence of plaque would have been under-diagnosed in around 
13% of patients. Although exploration of the femoral territories may cause 
discomfort to the patient, it does not increase the cost of the exploration and 
provides valuable information for a significant proportion of patients. 
Interestingly, it was found that CKD progression is associated with 
atheromatosis progression. Although both occur concurrently and we cannot 
use one as a predictor of the other, the results demonstrate that both 
pathologies are closely related and that patients who progress in one are more 
likely to progress in the other, independently of other factors. 
The multivariate logistic regression model to predict progression of 
atheromatosis in the whole population showed traditional risk factors similar to 
the results of the MESA30, the Rotterdam31 and TromsØ studies32, although we 
found multiple interactions between CKD stages and the other clinical variables.  
However, being diabetic predicted atheromatosis progression independently of 
the CKD stage. Furthermore, having plaque at baseline and high levels of 
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ferritin also predicted the progression of atheromatosis independently of the 
degree of renal function, although this effect is modified by age, being lower in 
older patients.  
The stratified analysis showed that in CKD stage 3, SBP, smoking and diabetes 
predicted progression of atheromatosis. Therefore, in early stages of CKD, we 
can use classic cardiovascular risk factors to predict plaque progression.  
Additionally, high phosphate levels and low 25-OH vitamin D levels were also 
predictors of atheromatosis progression. Indeed, a potential role for phosphate 
and 25-OH vitamin D levels has been previously suggested in the progression 
of atherosclerosis.33-37 Furthermore, a significant interaction between phosphate 
levels and age was found, showing that when phosphate levels are over 3.6 
mg/dL, the association with age is much stronger. This is consistent with 
previous results only showing a phosphate binder benefit in older patients38. 
However, in our study, patients treated with phosphate binders seemed to have 
lower odds of atheromatosis progression, independently of their age. On the 
other hand, the association with age is minor in patients with plaque already at 
baseline because this in itself is a high risk condition.  In CKD stages 4-5 new 
risk factors appear, like the ferritin levels. Thus, it seems that inflammation 
starts to play a role in atheromatous plaque progression in predialysis stages. In 
dialysis patients, risk factors for atheromatosis progression are completely 
different. A paradoxical association was observed with cholesterol levels. 
However, history of dyslipidemia still persists as a risk factor, suggesting that 
actual low cholesterol levels could be a reflection of a state of malnutrition, as 
reflected by a better prognosis in patients with a higher BMI.  Uric acid appears 
as a predictor of atheromatosis progression, agreeing with previous results.39;40 
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Inflammation, estimated by high ferritin levels, persists as an important risk 
factor for atheromatosis. Low vitamin D levels are also predictors of plaque 
progression, confirming previous experimental studies showing the effect of a 
vitamin D deficit on atheromatosis.41-43 A significant interaction between vitamin 
D and BMI was also found. Only patients with low to moderate BMI showed 
lower odds of progression with high vitamin D levels.  The results also confirm 
that higher cIMT emerges as a predictor of atheromatosis progression in this 
group of patients.  
The main strength of this study is the large number of patients with longitudinal 
observations, which allows us to make predictive associations between multiple 
factors and atheromatosis progression and to adjust for multiple confounders. 
Another strength is that the vascular exploration was performed by the same 
team and evaluated by a single reader.   
This study also has several limitations. First, the large number of dropouts 
lowers the statistical power of the study. Given that only patients without 
cardiovascular events were evaluated at baseline and follow-up and most of the 
dropouts were either patients receiving a transplant or patients who died, a 
subpopulation with intermediate health status was probably being analyzed. In 
addition, plaque volume and density were not measured. Finally, FGF23 levels 
were lacking, which could have been mediating the effects of high phosphate in 
atheromatosis and only a small portion of patients had levels of proteinuria.  
In summary, data presented here demonstrate the validity of the determination 
of atheroma plaque presence by arterial ultrasound as a powerful tool to predict 
atheromatosis progression in CKD patients. The factors predicting 
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atheromatosis progression in each CKD stage are different. Furthermore, CKD 
progression and atheromatosis progression are closely associated. 
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Table 1. Main Baseline Characteristics in Participants according to CKD stage 
(n=1553). Quantitative data are expressed as mean and standard deviation (SD) or median, 
(p25, p75) depending on the normality of the distribution. Qualitative variables are expressed as 
N (%).  aAbdominal obesity: waist circumference ≥ 102 cm (male) or ≥ 88  (female), not 
measured in peritoneal dialysis patients. bHbA1c was measured only in diabetic patients. cUrine 
Albumin-to-Creatinine Ratio (UACR) and CKD progression not measured in dialysis patients. dIn 
patients with plaque at baseline. ecIMT: Common carotid artery intima media thickness. p values 
reflect differences between CKD stages. 
  CKD 3 CKD 4-5 CKD 5D p 
N 709 (46) 578 (37) 266 (17)  
Males 481 (67.8) 328 (56.7) 147 (55.3) <0.001 
Age (years) 63 (56, 69) 61 (51, 68) 55 (44, 66) <0.001 
Race (white)  700 (98.7) 562 (97.2) 247 (92.9) <0.001 
Medical history     
Smoker  413 (58.3) 317 (58.4)  139 (52.2) <0.001 
Diabetes 186 (26.2) 158 (27.3) 40 (15) <0.001 
Hypertension 645 (91) 550 (95.2) 232 (87.2) <0.001 
Dyslipidemia  506 (71.4) 409 (70.8) 151 (56.8) <0.001 
Etiology of renal disease     
Vascular disease 217 (37.2) 94 (18.4) 9 (11) <0.001 
Diabetic Nephropathy 84 (14.4) 90 (17.6) 25 (11.5) 0.12 
Others 282 (48.4) 326 (63.9) 169 (77.5) <0.001 
Body mass index (kg/m2) 28.8 (26, 31.8) 27.7 (24.9, 32) 26.1 (23.1, 30) <0.001 
Abdominal obesitya 142.5 (52.6) 294 (51.9) 84 (45.4)a 0.21 
Systolic BP (mmHg) 142.4 (19.5) 143.9 (20.5) 139.4 (23) 0.03 
Diastolic BP (mmHg) 81.9 (10.07) 82 (11.1) 80.5 (13.5) 0.33 
Pulse pressure (mmHg) 60.5 (15.8) 61.9 (18) 58.8 (18.6) 0.10 
Time on dialysis (months)   16.6 (7, 33.8) -- 
Total Cholesterol (gr/dL) 188.3 (36.9) 177.9 (37.1) 165.03 (45.2) <0.001 
LDL Cholesterol (gr/dL) 111 (32.5) 101.1 (32.3) 90.9 (34.7) <0.001 
HDL Cholesterol (gr/dL) 48 (40, 58) 47 (37.8, 59) 45 (36.4, 56) <0.001 
Non-HDL Cholesterol (mg/dL) 138.2 (34.8) 128.9 (35.1) 118.8 (43.3) <0.001 
Triglycerides (mg/dL) 122 (92, 174) 125 (91, 171) 121 (90, 170) 0.95 
HbA1c (%)b 6 (5.5, 6.7) 5.9 (5.4, 6.8) 5.1 (4.8, 5.8) <0.001 
Albumin (gr/dL) 4.2 (0.4) 4.1 (0.4) 3.8 (0.4) <0.001 
Hematocrit (%) 
Ferritin (mg/dL) 
41.6 (4.7) 
110.1 (60, 210) 
37.4 (4.2) 
148 (74, 268) 
35.8 (4.4) 
316 (159, 474) 
<0.001 
<0.001 
Corrected calcium (mg/dL) 9.27 (0.5) 9.2 (0.5) 9.1 (0.7) <0.001 
Phosphate (mg/dL) 3.3 (0.5) 4 (0.7) 4.8 (1.2) <0.001 
PTH (pg/mL) 
Uric Acid (mg/dL) 
68.7 (49.2, 98) 
6.79 (1.5) 
137 (91.6, 212) 
6.99 (1.6) 
226 (145, 344) 
6.02 (1.4) 
<0.001 
<0.001 
25-hydroxy vitamin D (pg/mL) 15.2 (11.8,20.1) 15.7 (11.3, 19.9) 13.6 (10, 18.9) <0.001 
1-25-hydroxy vitamin D (ng/mL) 19.3(14, 26.3) 15.3 (10.1, 22.2) 6.2 (4.1, 9.9) <0.001 
hs C-Reactive Protein (mg/L) 1.8 (0.9, 3.7) 1.72 (0.84, 3.98) 2.5 (0.99, 6.6) 0.01 
UACR (mg/g)c 51.5 (7.6, 264) 173.4 (30, 677) nac <0.001 
CKD progression 
Atheromatosis progression 
12 (1.7) 
418  (59) 
146 (25.3) 
344 (59.5) 
na 
168 (63.2) 
 
<0.001 
0.47 
Treatments     
Antihypertensive 655 (92.4) 560 (96.9) 194 (72.9) <0.001 
Statins 425 (67.8) 370 (64) 136 (51.1) <0.001 
Phosphate binders 38 (5.4) 186 (32.2) 210 (78.9) <0.001 
Vitamin D 128 (18.1) 281 (48.6) 136 (51.1) <0.001 
Antiplatelet drugs 153 (21.6) 134 (23.2) 76 (28.6) 0.07 
Plaque presence 495 (69.8) 385 (66.6) 186 (69.9) 0.41 
Multiple plaquesd 363 (73.3) 310 (80.5) 143 (76.9) 0.12 
Number of territories with plaqued 3 (1, 4) 3 (2, 4) 3 (2, 4.3) 0.88 
cIMT (mm)e 0.74 (0.14) 0.7 (0.1) 0.7 (0.1) <0.001 
Pathologic Ankle-Brachial index 147 (20.7) 126 (21.9) 88 (33.2) <0.001 
ABI ≤ 0.9 109 (15.4) 76 (13.2) 30 (11.3) 0.22 
ABI ≥ 1.4 38 (5.4) 50 (8.7) 58 (21.9) <0.001 
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Table 2. Baseline factors associated with progression of atheromatosis in all 
patients (n=1553). Quantitative data are expressed as mean and standard deviation (SD), or 
median, (p25, p75) depending on the normality of the distribution. Qualitative variables are 
expressed as N (%).   aAbdominal obesity: waist circumference ≥ 102 cm (male) or ≥ 
88  (female), not measured in Peritoneal dialysis patients. bHbA1c was measured only in 
diabetic patients. cUrine Albumin-to-Creatinine Ratio (UACR): not measured in dialysis patients. 
dIn patients with plaque at baseline. ecIMT: Common carotid artery intima media thickness. 
  ATHEROMATOSIS 
PROGRESSION 
NO ATHEROMATOSIS 
PROGRESSION p 
N 930 (59.8) 623 (40.1)  
Males 608 (67.8) 348 (56.7) <0.001 
Age (years) 64 (56, 70) 57 (43, 66) <0.001 
Race (white) 914 (98.3) 595 (95.5) <0.001 
Medical history    
Smoker 561 (60.3) 308 (49.4) <0.001 
Hypertension 877 (94.3) 550 (88.3) <0.001 
Diabetes 278 (29.9) 106 (17) <0.001 
Dyslipidemia  674 (72.5) 392 (62.9) <0.001 
Etiology of renal disease    
Vascular disease 210 (27.1) 125 (23.3) 0.12 
Diabetic Nephropathy 143 (18.5) 56 (10.4) <0.001 
Others  422 (54.5) 355 (66.2) <0.001 
Body mass index (kg/m2) 28.5 (25.4, 31.8) 27.7 (24.5, 31.6) <0.001 
Abdominal obesitya 469 (53.8) 287 (48.1) 0.03 
Systolic BP (mmHg) 144.8 (21.2) 138.9 (19) <0.001 
Diastolic BP (mmHg) 81.57 (11.4) 81.96 (10.7) <0.001 
Pulse pressure (mmHg) 63.29 (18.0) 57.01(15.2) <0.001 
CKD stages   0.48 
Stage 3 418 (44.9) 291 (46.7)  
Stage 4-5 344 (37) 234 (37.6)  
Stage 5D 168 (18.1) 98 (15.7)  
Time on dialysis (months) 17.5 (6.7, 33.4) 16.3 (7.4, 34.2) 0.82 
Total Cholesterol (gr/dL) 179.9 (39.8) 181.8 (38.6) 0.27 
LDL Cholesterol (gr/dL) 102.9 (33.5) 105.2 (33.7) 0.26 
HDL Cholesterol (gr/dL) 49 (15.2) 50.1 (14.7) 0.11 
Non-HDL Cholesterol (mg/dL) 131.1 (38.3) 131.7 (35.4) 0.49 
Triglycerides (mg/dL) 126 (94, 176.5) 118 (86, 165) <0.001 
HbA1c (%)b 6 (5.4, 6.7) 5.7 (5.2, 6.4) <0.001 
Albumin (gr/dL) 4.2 (0.4) 4.1 (0.4) 0.93 
Hematocrit (%) 39 (5) 39.2 (5.1) 0.51 
Ferritin (mg/dL) 160.1 (78, 313.2) 136.2 (66.5, 242) <0.001 
Corrected calcium (mg/dL) 9.2 (0.5) 9.2 (0.5) 0.10 
Phosphate (mg/dL) 3.9 (0.9) 3.8 (0.9) 0.42 
PTH (pg/mL) 
Uric acid (mg/dL) 
114.8 (68.4, 193.8) 
6.71 (1.6) 
101 (62.3, 186) 
6.78 (1.6) 
0.08 
0.29 
25-hydroxy vitamin D (pg/mL) 14.7 (11.2, 19.1) 15.9 (11.9, 20.7) <0.001 
1-25-hydroxy vitamin D (ng/mL) 16.1 (10.3, 22.9) 15.6 (10.1, 22.7) 0.83 
hs C-Reactive Protein (mg/L) 2 (0.96, 4.7) 1.77 (0.8, 3.8) <0.001 
UACR (mg/g)c 92.5 (12, 438.6) 100.8 (13.7, 404) 0.83 
Treatments    
Antihypertensive 857 (92.2) 552 (88.6) 0.02 
Hypolipemiant 578 (69.5) 353 (60.5) <0.001 
Phosphate binders 257 (27.6) 177 (28.4) 0.74 
Vitamin D 334 (35.9) 211 (33.9) 0.41 
Antiplatelet drugs 238 (25.6) 125 (20.1) 0.01 
Plaque at baseline 733 (78.8) 333 (53.5) <0.001 
Multiple plaquesd 562 (76.6) 254 (76.2) 0.89 
Number of territories with plaqued 2 (1, 4) 1 (0, 3) 0.43 
cIMT (mm)e 0.74 (0.14) 0.67 (0.13) <0.001 
Pathologic Ankle-Brachial index 226 (24.3) 135 (21.7) 0.24 
ITB ≤ 0.9 128 (13.8) 87 (14) 0.90 
ITB ≥ 1.4 98 (10.5) 48 (7.7) 0.06 
CKD progression 109 (14.3) 49 (9.4) <0.001 
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Table 3. Multivariate logistic regression to model plaque progression at 24 months stratified by CKD 
stage 3, 4-5 and 5D. Results are expressed as *OR (Exponential β for independent variables with interactions) and 
95% Confidence interval (95% CI). The following variables were introduced to build multivariate models by CKD stages 
because they were significant on bivariate testing or potential confounders: sex, CKD stage, age (decades), diabetes, 
smoking, dyslipidemia, SBP ≥ 150 mmHg (highest tertile in CKD stage 3), Pulse pressure, BMI, basal plaque, cIMT, 
ferritin > 220 mg/dL (Highest tertile in CKD Stage 4-5), uric acid, CRP, Total cholesterol> 180 mg/dL (the level of 180 
was selected based in clinical criteria), LDL-cholesterol, hematocrit, statins, antiplatelet drugs, triglycerides, 25-OH-
vitamin D (ln 25-0H-vitamin D for interactions and CKD Stage 4-5 and 5D, and 25-OH-vitamin D ≥ 18.1 (Vitamin D 
highest tertile in CKD Stage 3),  (P highest tertile in CKD stage 3 > 3.6 mg/dL), PTH. Only significant variables in 
multivariate analysis in each group of CKD were included in the final model. The Exp β  and p values of the rest of the 
variables are the values obtained if added to the final model.  CKD stage 3. Hosmer Lemeshow= 0.46, AUC= 0.72. CKD 
stage 4-5. Hosmer Lemeshow= 0.82 AUC= 0.74. CKD stage 5D. Hosmer Lemeshow=0.16, AUC=0.83. 
 
 
 
 
 
 CKD Stage 3 CKD Stage 4-5 CKD Stage 5D 
 OR* (95% CI) p-value OR* (95% CI) p-value OR* (95% CI) p-value 
Age (decades) 1.65 (1.24-2.25) <0.001 1.95 (1.43-2.75) <0.001 1.48 (1.07-2.06)* 0.02 
Smoking (current & former vs no) 1.77 (1.24-2.55) <0.001 3.95 (1.91-8.50) <0.001 1.32 (0.64-2.74) 0.45 
Diabetes (yes vs. no) 1.59 (1.06-2.41)* 0.03 1.45 (0.92-2.31) 0.11 2.37 (0.66-10.74) 0.22 
SBP ≥ 150 mmHg 1.46 (1.01-2.12)* 0.04 2.84 (1.86-4.39)* <0.001 0.64 (0.29-1.40) 0.26 
P >3.6 mg/dL 1.62 (1.09-2.43) 0.02 0.84 (0.54-1.30) 0.44 0.80 (0.28-2.17) 0.66 
Phosphate binders use (yes vs. 
no) 
0.42 (0.19-0.88)* 0.02 0.78 (0.51-1.19) 0.25 1.38 (0.56-3.34) 0.48 
25-OH-vitamin D (pg/mL) 0.62 (0.43-0.89)* 0.01 1.34 (0.82-2.20) 0.24 0.08 (0.01-0.47) 0.01 
Plaque at baseline (yes vs. no) 1.33 (0.85-2.06) 0.21 3.16 (1.68-6.02) <0.001 1.20 (0.50-2.82) 0.67 
Age*P 1.70 (1.16-2.54) 0.01 0.95 (0.63-1.42) 0.22 1.02 (0.44-2.09) 0.95 
Age*Plaque at baseline 0.66 (0.45-0.96) 0.03 0.62 (0.41-0.93) 0.02 0.58 (0.29-1.11) 0.11 
Ferritin > 220 ng/mL 1.33 (0.82-2.18) 0.25 1.37 (0.89-2.14) 0.16 2.54 (1.20-5.52)* 0.02 
Age*Ferritin > 220 ng/mL 0.91 (0.58-1.49) 0.69 0.66 (0.45-0.97) 0.04 1.22 (0.70-2.11) 0.95 
Smoking*Plaque at baseline 0.45 (0.19-1.02) 0.06 0.32 (0.13-0.78) 0.01 2.75 (0.60-13.12) 0.20 
BMI (kg/m2) 0.99 (0.96-1.03) 0.76 1.01 (0.97-1.05) 0.67 0.79 (0.66-0.93) 0.01 
Dyslipidemia (yes vs. no) 1.27 (0.86-1.85) 0.23 1.39 (0.89-2.15) 0.14 5.14 (2.34-12.01)* <0.001 
Cholesterol > 180 mg/dL 1.15 (0.81-1.63) 0.45 1.06 (0.71-1.6) 0.77 0.31 (0.13-0.70)* 0.01 
Uric acid (mg/dL) 1.08 (0.96-1.21) 0.22 1.02 (0.91-1.16) 0.72 1.38 (1.06-1.84)* 0.02 
cIMT (mm) 1.07 (0.93-1.23) 0.37 1.12 (0.95-1.33) 0.18 1.66 (1.22-2.32)* <0.001 
Ln 25-OH-vitamin D*BMI 1.01 (0.94-1.09) 0.82 0.95 (0.87-1.03) 0.22 1.16 (1.02-1.33) 0.02 
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FIGURE LEGENDS 
 
Figure 1. Boxplot showing the number of territories with plaque at baseline and after 
24 months of follow-up according to the presence of plaque at baseline. The highest 
whisker indicates the last value that is less than or equal to the result of the standard 
formula p75+1.5*IQR. Circles or stars represent readings that are outliers or far 
outliers, respectively (defined as higher than p75 + 1.5*IQR or p75 + 3*IQR, 
respectively). p<0.001 between progression in patients with plaque at baseline vs. 
progression in patients without plaque at baseline. 
 
Figure 2. Percentage and CI (95%) of patients that showed atheromatosis progression 
according to CKD progression after 24 months. p<0.001 
 
Figure 3.  Percentage of patients with progression of atheromatosis over 24 months 
according to basal plaque and CKD progression in CKD stages 3 and 4-5.  p<0.001 
between progression in patients with neither CKD progression nor plaque at baseline 
and progression in patients with CKD progression and plaque at baseline.  
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